These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 28832517)

  • 1. Therapeutic Potential of Amino Acids in Inflammatory Bowel Disease.
    Liu Y; Wang X; Hu CA
    Nutrients; 2017 Aug; 9(9):. PubMed ID: 28832517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases.
    Billmeier U; Dieterich W; Neurath MF; Atreya R
    World J Gastroenterol; 2016 Nov; 22(42):9300-9313. PubMed ID: 27895418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into inflammatory bowel disease pathophysiology: paving the way for novel therapeutic targets.
    Stefanelli T; Malesci A; Repici A; Vetrano S; Danese S
    Curr Drug Targets; 2008 May; 9(5):413-8. PubMed ID: 18473770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells in IBD pathogenesis: an area of therapeutic opportunity?
    Bates J; Diehl L
    J Pathol; 2014 Jan; 232(2):112-20. PubMed ID: 24122796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
    Hasenoehrl C; Storr M; Schicho R
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):329-337. PubMed ID: 28276820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Regulation of inflammatory bowel disease by amino acids].
    Sun Q; Wu H; Li S; Sun Z
    Sheng Wu Gong Cheng Xue Bao; 2022 Jun; 38(6):2128-2138. PubMed ID: 35786467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Status of Medical Therapy for Inflammatory Bowel Disease: The Wealth of Medications.
    Nadpara N; Reichenbach ZW; Ehrlich AC; Friedenberg F
    Dig Dis Sci; 2020 Oct; 65(10):2769-2779. PubMed ID: 32661765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlling leukocyte trafficking in IBD.
    Veny M; Fernández-Clotet A; Panés J
    Pharmacol Res; 2020 Sep; 159():105050. PubMed ID: 32598943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in understanding the role of cytokines in inflammatory bowel disease.
    Bevivino G; Monteleone G
    Expert Rev Gastroenterol Hepatol; 2018 Sep; 12(9):907-915. PubMed ID: 30024302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased arterial stiffness in inflammatory bowel diseases is dependent upon inflammation and reduced by immunomodulatory drugs.
    Zanoli L; Rastelli S; Inserra G; Lentini P; Valvo E; Calcagno E; Boutouyrie P; Laurent S; Castellino P
    Atherosclerosis; 2014 Jun; 234(2):346-51. PubMed ID: 24732573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactive lipids in inflammatory bowel diseases - From pathophysiological alterations to therapeutic opportunities.
    Alhouayek M; Ameraoui H; Muccioli GG
    Biochim Biophys Acta Mol Cell Biol Lipids; 2021 Feb; 1866(2):158854. PubMed ID: 33157277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Damage-associated molecular patterns in inflammatory bowel disease: From biomarkers to therapeutic targets.
    Nanini HF; Bernardazzi C; Castro F; de Souza HSP
    World J Gastroenterol; 2018 Nov; 24(41):4622-4634. PubMed ID: 30416310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential role of nutraceutical compounds in inflammatory bowel disease.
    Larussa T; Imeneo M; Luzza F
    World J Gastroenterol; 2017 Apr; 23(14):2483-2492. PubMed ID: 28465632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New pathophysiological insights and modern treatment of IBD.
    Engel MA; Neurath MF
    J Gastroenterol; 2010 Jun; 45(6):571-83. PubMed ID: 20213337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory Bowel Disease Drugs: A Focus on Autophagy.
    Hooper KM; Barlow PG; Stevens C; Henderson P
    J Crohns Colitis; 2017 Jan; 11(1):118-127. PubMed ID: 27381462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of inflammatory bowel disease (IBD).
    Pithadia AB; Jain S
    Pharmacol Rep; 2011; 63(3):629-42. PubMed ID: 21857074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State of the art: IBD therapy and clinical trials in IBD.
    Isaacs KL; Lewis JD; Sandborn WJ; Sands BE; Targan SR
    Inflamm Bowel Dis; 2005 Nov; 11 Suppl 1():S3-12. PubMed ID: 16254481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Drug Repurposing Approach for Therapeutic Intervention of Inflammatory Bowel Disease.
    Bhat MA; Usman I; Dhaneshwar S
    Curr Rev Clin Exp Pharmacol; 2024; 19(3):234-249. PubMed ID: 37859409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current overview of opioids in progression of inflammatory bowel disease; pharmacological and clinical considerations.
    Lashgari NA; Roudsari NM; Zandi N; Pazoki B; Rezaei A; Hashemi M; Momtaz S; Rahimi R; Shayan M; Dehpour AR; Abdolghaffari AH
    Mol Biol Rep; 2021 Jan; 48(1):855-874. PubMed ID: 33394234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.
    Sartor RB
    Gastroenterol Clin North Am; 1995 Sep; 24(3):475-507. PubMed ID: 8809232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.